

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Berotralstat for preventing acute attacks of hereditary
angioedema**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

None identified for berotralstat.

However 2 potential equality issues were discussed during the development of a related technology appraisal (TA606 [Lanadelumab for preventing recurrent attacks of hereditary angioedema](#)). During this appraisal, the committee discussed potential equality issues for the comparator C1-INH because it is based on human or animal products and may not be acceptable to some people. The committee considered the acceptability of human plasma-derived C1-INH (Berinert and Cinryze) and non-plasma-derived C1-INH based on animal products (Ruconest). Lanadelumab is manufactured in Chinese Hamster Ovary (CHO) cells. The committee heard from clinical experts that some people may prefer to use the animal-based C1-INH but understood that it was not commonly used in clinical practice. It noted that some religious groups may refuse human plasma-derived products but understood that the animal-based C1-INH may be used as an alternative for these people.

The committee was also aware that oral treatment such as attenuated androgens can affect female fertility and are therefore not appropriate for women of child-bearing age. However, the committee noted that C1-INH was available if long-term prophylaxis with oral therapy is contraindicated, for example in pregnant women.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

It is unlikely that the equality issues above will impact on the recommendations but the committee should consider:

1. the treatment options available to women who may wish to become pregnant, to ensure that any recommendations do not directly or indirectly discriminate on the basis of gender. The final scope includes a number of interventions that do not impact on fertility.
2. the treatment options available for people who are unwilling to have human or animal products, to ensure that any recommendations do not directly or indirectly discriminate on the basis of religion. The final scope includes a number of interventions that are not based on human or animal products.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name):Ross Dent.....

Date: 01/10/2020